Research Library
749 papers · 104 analysis articles
Research Analysis
Curated deep-dives into the latest peptide research
Exploring BPC-157 Safety and Pharmacokinetics: A Phase I Trial
BPC-157 Study Shows Promise in Accelerating Recovery from Hamstring Injuries
FDA Paves Way for New Testosterone Therapy Research in Men
Semaglutide Injection Remains on Market; FDA Clears Path for Continued Use
FDA Extends Pharmacy Compounding Advisory Committee’s Charter for Peptide Research and Patient Safety
FDA Proposes to Restrict Use of Semaglutide and Other Peptide Drugs in Compound Form
Papers Database
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.
Semaglutide in Adults with Type 1 Diabetes and Obesity.
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.
First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.
A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment.
Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
Deucrictibant for angioedema due to acquired C1-inhibitor deficiency: A randomized-controlled trial.
Acute salivary antimicrobial peptide secretion response to different exercise intensities and durations.
Obesity, Cardiovascular Disease, and the Promising Role of Semaglutide: Insights from the SELECT Trial.
Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial.
Collagen peptides supplementation improves function, pain, and physical and mental outcomes in active adults.
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
Efficacy and Safety of Aflapin®, a Novel
Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.
Immune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial.
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Safety Profile of Bremelanotide Across the Clinical Development Program.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Safety and immunogenicity of a mosquito saliva peptide-based vaccine: a randomised, placebo-controlled, double-blind, phase 1 trial.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.
Effects of Meditation and Music-Listening on Blood Biomarkers of Cellular Aging and Alzheimer's Disease in Adults with Subjective Cognitive Decline: An Exploratory Randomized Clinical Trial.
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.